• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
XUE Jing,HUANG Baobin,ZHONG Weixuan,WANG Shan.Comparison study for the re-inspection/re-examination procedures of drugs, medical devices, and cosmetics[J].Journal Of Pharmaceutical Research,2026,45(7):830-833,840[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 952times   Download 575次 QR Code for this article
Scan with your phone!
药品医疗器械化妆品复验/复检程序对比
薛晶,黄宝斌,仲宣惟,王杉
Font:Larger+|Default|Smaller-
(中国药品检定研究院,北京 102629)
摘要:
本文系统比较了药品、医疗器械、化妆品在复验/复检程序上的法规异同。研究发现,现行法规在受理机构、检验时限等核心环节规定上存在不一致;同时面临样品封签管理不统一、报告送达时限执行不一致、电子检验报告法律效力未明确、多方重复申请问题突出、复验/复检机构独立性规定不一致、无法受理时缺乏终止机制等共性问题,影响了救济效率与公正性。建议构建规范一致的程序框架,明确电子报告法律效力,统一送达认定标准与多方申请规则,探索复验/复检与异议区别处理,并健全沟通机制与信息平台建设,以提升监管公信力与申请人权利保障水平。
关键词:  药品  医疗器械  化妆品  复验程序  复检程序
DOI:10.13506/j.cnki.jpr.2026.07.017
基金项目:
Received Date:April 20, 2026   Revision Date:May 18, 2026   Publication Date:July 31, 2026
Comparison study for the re-inspection/re-examination procedures of drugs, medical devices, and cosmetics
XUE Jing,HUANG Baobin,ZHONG Weixuan,WANG Shan
(National Institutes for Food and Drug Control, Beijing 102629, China)
Abstract:
A systematic comparison was conducted on the regulatory similarities and differences in the re-inspection/re-examination procedures among drugs, medical devices, and cosmetics. It was found that inconsistencies existed in the current regulations regarding core procedures such as the accepting institutions and inspection time limits. Meanwhile, common problems were identified, including non-unified sample sealing management, inconsistent implementation of report delivery time limits, unclear legal validity of electronic inspection reports, prominent issues of duplicate applications by multiple parties, inconsistent provisions on the independence of re-inspection/re-examination institutions, and the lack of termination mechanisms when applications could not be accepted, all of which affected the efficiency and impartiality of the remedy process. To enhance regulatory credibility and the protection of applicants' rights, it was suggested that a standardized and consistent procedural framework should be established, the legal validity of electronic reports should be clarified, unified standards for delivery confirmation and multi-party application rules should be established, differentiated treatment of re-inspection/re-examination and objections should be explored, and communication mechanisms and information platform construction should be improved.
Key words:  Drugs  Medical devices  Cosmetics  Re-inspection procedure  Re-examination procedure
Today's Visits:511    Total Visits:2383242
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.